0
Please log in or register to do it.

Gemvax & Kael

Gemvax & Kael

(Seoul = Larose.VIP) Reporter Cho Hyun-young = Gemvax & KAEL, a new drug development company, announced on the 13th that it has received approval from the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial plan (IND) for ‘GV1001’, a candidate for the treatment of progressive supranuclear palsy (PSP). revealed.

Accordingly, the company plans to evaluate the effectiveness and safety of GV1001 on 150 PSP patients at 30 to 40 institutions in the United States.

The company explained that PSP is an atypical Parkinson’s syndrome, and the disease progresses faster than typical Parkinson’s disease and does not respond well to drugs used for Parkinson’s disease.

Gemvax[082270]is conducting phase 2 clinical trials targeting PSP for this candidate material in Korea and is also planning to apply for clinical trials in the UK and the European Medicines Agency (EMA).

A Gemvax official said, “GV1001 is a new drug with a confirmed mechanism for improving the immune environment in the brain and reducing inflammation.” He added, “As the treatment effect has been confirmed on the global stage following domestic use, we are working hard to make GV1001 the world’s first PSP treatment.” “I will concentrate all my capabilities,” he said.

hyun0@yna.co.kr

Report to KakaoTalk okjebo 2024/02/13 15:14 Sent

“Ulsan University Medical School, support for quick local return”... City, meeting to secure doctor manpower
Chungbuk Medical Association participated in a rally against the expansion of medical schools on the 15th.

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *